Germany approves first trial of Covid-19 vaccine candidate
The trial, only the fourth worldwide of a preventive agent targeting the virus behind the global pandemic, will be conducted on 200 healthy people aged between 18 and 55 in the first stage
FILE PHOTO: The headquarters of biopharmaceutical company BioNTech are seen in Mainz, Germany July 31, 2018. REUTERS/Ralph Orlowski/File Photo
Germany's vaccines regulator approved live human testing of a potential vaccine against the Covid-19 virus developed by German biotech company BioNTech, the regulator said in a statement on Wednesday.
The trial, only the fourth worldwide of a preventive agent targeting the virus behind the global pandemic, will be conducted on 200 healthy people aged between 18 and 55 in the first stage, and on further people, including those at higher risk from the disease, in a second stage.
BioNTech said it was developing the vaccine candidate, named BNT162, together with its partner, pharma giant Pfizer. Tests of the vaccine were also planned in the United States, once regulatory approval for testing on humans had been secured there.
